Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan and 89Zr-DFO-girentuximab PET in Clear Cell Renal Cell Carcinoma
NCT07179770Phase 1Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of belzutifan in clear cell renal cell carcinoma (ccRCC), sponsored by NYU Langone Health. Primary endpoints: Change in Standardized Uptake Value (SUV) max uptake on 89Zr-DFO-girentuximab PET at Week 4, Standardized Uptake Value (SUV) peak uptake on 89Zr-DFO-girentuximab PET at Week 4 and 1 more. Planned start Sep 2025; status: withdrawn.
02
Drugs
belzutifan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07179770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07179770.